A

ANI Pharmaceuticals

D
ANIP
USD
-0.1
(-0.1712%)
Market Closed
10,593.00
Volume
4.43
EPS
-
Div Yield
49.000
P/E
1,226,263,323.39
Market Cap
Today
-0.1712%
1 Week
1.958%
1 Month
4.461%
6 Months
-12.710%
12 Months
-8.476%
Year To Date
5.749%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
I
ICLR
-8.905
(-3.9781%)
USD
P
PETQ
0
(0%)
USD
P
PAHC
0.595
(2.6034%)
USD
P
PRGO
1.57
(6.1933%)
USD
ZTS
ZTS
3.92
(2.3001%)
USD
IDXX
IDXX
10.09
(2.3838%)
USD
Z
ZBH
-2.495
(-2.244%)
USD
H
HSIC
-0.563
(-0.8044%)
USD
C
CAH
2.62
(2.2666%)
USD
L
LH
4.69
(2.0013%)
USD

Title:
ANI Pharmaceuticals

Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Do you need help or have a question?
Contact Us